Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:2/14/2008

d marketable securities at the end of

the fourth quarter of 2007 totaled approximately $93.2 million,

compared to approximately $109.4 million as of September 30, 2007, and

approximately $31.9 million as of December 31, 2006.

FINANCIAL GUIDANCE

The company anticipates that its current cash balance will be sufficient to fund operations through the Fiapta(TM) PDUFA action date and into the fourth quarter of 2008. Vanda plans to focus its efforts primarily on completing and reporting the top-line results for the ongoing VEC-162 Phase III chronic insomnia clinical trial and continuing essential Fiapta(TM) pre-launch commercial activities.

CONFERENCE CALL

The company has scheduled a conference call for today, Thursday, February 14, 2008 at 10:30 AM ET. During the call, Mihael H. Polymeropoulos, M.D., President and CEO, and Steven A. Shallcross, Sr. Vice President and CFO, will discuss quarterly results and other corporate activities. Investors can call 1-866-578-5747 (domestic) and 1-617-213-8054 (international) prior to the 10:30 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos. A replay of the call will be available Thursday, February 14, 2008, at 12:30 PM ET and will be accessible until Thursday, February 21, 2008, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 16341258.

The conference call will be broadcast simultaneously on the company's Web site, http://www.vandapharma.com. Investors should click on the Investor Relations tab and are advised to go to the Web site at least 15 minutes early to register, download, and install any necessary software. The call will also be archived on the Vanda Web site for a period of 30 days, through March 15, 2008.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharma
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vion Pharmaceuticals Holds Special Meeting of Stockholders
2. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
3. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
9. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
10. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 AACC, a global scientific and medical ... unveiled an updated brand identity today that reflects the ... changing healthcare environment and continue to do what they ... get the care they need. " ... an essential role in saving lives and making people ...
(Date:8/1/2014)... , August 1, 2014 According ... Research "Biophotonics Market - Global Industry Analysis, Size, Share, ... was valued at USD 25.16 billion in 2013, which ... growing at a CAGR of 10.4% from 2014 to ... at  http://www.transparencymarketresearch.com/biophotonics-market.html Increasing demand for accurate ...
(Date:8/1/2014)... Mass. (PRWEB) August 01, 2014 BCC ... RNAi DRUG DELIVERY: TECHNOLOGIES AND GLOBAL MARKETS , ... technologies is expected to grow to nearly $38.8 billion ... (CAGR) of 27.2%. The aptamer delivery category, the fastest ... phenomenal 58.2% CAGR. , The field of RNAi therapeutics ...
(Date:8/1/2014)... Testing the mechanical properties of microtissues ... embryonic development. How and why embryonic stem ... distinct tissues is important because abnormalities can lead ... Melissa Kinney, and Rabbia Saeed worked from the ... to control many aspects of embryo development. ...
Breaking Biology Technology:AACC Debuts Refreshed Brand Identity 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Study Links Biomechanics and Gene Expression in Stem Cells 2
... long-awaited speaking faculty for the September Pharma ChemOutsourcing ... conference website reports Mark Alexay, President of Apaporis ... comprised of 100 speakers from pharmaceutical companies and ... the pipeline. The speaker list may be viewed ...
... Christine Lawless, MD, has accepted the position as ... continuing medical education (CME), beginning March 2, 2009. Recognized ... medicine cardiology, Dr. Lawless recently completed her clinical tenure ... where she was Associate Professor of Internal Medicine and ...
... Endpoints,NEW YORK, March 10 Intra-Cellular Therapies, Inc. today ... trial in patients with Sleep Maintenance Insomnia (SMI). ... wave sleep and decreased the duration of wake after ... prespecified primary and key secondary endpoints of the trial. ...
Cached Biology Technology:Pharma ChemOutsourcing Unveils 100 Pharma & Biotech Speaker Faculty for 2009 Conference September 14-16 in Long Branch, NJ 2Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 3Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 4Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 5Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 6Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 7
(Date:8/1/2014)... 1, 2014Lesbian, gay, bisexual, and transgender individuals who want ... as some of their heterosexual and cisgendered peers, such ... additional physiological and legal challenges to become parents. ... assisted reproduction options is presented in the article " ... published in LGBT Health , a ...
(Date:8/1/2014)... group of marine mammals have officially named a ... Sousa sahulensis , according to the Wildlife ... study describing the newly named species is the ... all available historical records, physical descriptions, and genetic ... cetaceans ranging from the coast of West Africa ...
(Date:8/1/2014)... tricky enough. Knowing what causes them at the molecular ... Iowa researchers have created the most detailed map to ... associated with blinding diseases, such as age-related macular degeneration. ... the choroid, which supplies blood and oxygen to the ... in the abundance of proteins in different areas of ...
Breaking Biology News(10 mins):Advances in assisted reproduction create more options & new legal issues for LGBT couples 2Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3A map for eye disease 2
... A new technique for transplanting the ovaries of women ... cancer treatment was outlined to the 25th annual conference ... today (Monday 29 June). Dr. Pascal Piver, ... Limoges, France, described a new, two-step method of ovarian ...
... Shingu City, Japan--Deepsea Drilling Vessel CHIKYU has resumed IODP ... the Kii Peninsula of Japan. The scientific drilling expedition,s ... meters. Following sea floor surveys, the crew began fitting ... an upper section of the first borehole to be ...
... June 2009 Elsevier, the leading publisher of scientific, ... the highlights of its journal impact factor performance in ... factors (IF) increase from 2007 to 2008. According to ... journals took the #1 position in 51 categories (of ...
Cached Biology News:Ovarian transplantation: First baby is born after a new technique 2First riser-drilling research operations undertaken 2Elsevier announces 2008 journal impact factor highlights 2Elsevier announces 2008 journal impact factor highlights 3
... long electrophoresis hood is a ... systems. Placed on the transilluminator, ... place and provides a darkroom ... the lab bench. This 15.2 ...
... derived from frozen embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 7 ... are large (3-5 mm in diameter) in ...
... are derived from frozen embedded tissue blocks, ... procedures to ensure the highest quality. Tissues ... one block, sectioned at a thickness of ... are large (3-5mm in diameter) in comparison ...
... microarrays are derived from Paraffin embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5mm in diameter) ...
Biology Products: